SCHEMBL3744273

SCHEMBL3744273

Cc1nc(Oc2ccc(F)c(F)c2)sc1C=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.36
MAPT P10636 3/20 0.34
KLKB1 P03952 1/20 0.34
FFAR4 Q5NUL3 1/20 0.33
ALDH1A1 P00352 2/20 0.33
MAP4K4 O95819 1/20 0.33
HTR2A P28223 1/20 0.33
SLC6A4 P31645 1/20 0.33
KMT2A Q03164 4/20 0.32
LMNA P02545 1/20 0.32
HPGD P15428 1/20 0.32
MEN1 O00255 3/20 0.32
NPC1 O15118 1/20 0.32
GAA P10253 1/20 0.32
RAB9A P51151 1/20 0.32
TRPA1 O75762 1/20 0.32
EPHX2 P34913 4/20 0.31
LTA4H P09960 1/20 0.31
PTGS2 P35354 1/20 0.31
FFAR1 O14842 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21274246 0.84 ALDH1A1 (0.40) SOS1MAPTALDH1A1KMT2AHPGD
SCHEMBL2556124 0.83 KMT2A (0.44) SOS1MAPTALDH1A1MAP4K4KMT2A
SCHEMBL3739346 0.78 LMNA (0.41) MAPTALDH1A1KMT2ALMNAHPGD
SCHEMBL2558710 0.69 MAPT (0.49) MAPTALDH1A1HTR2ASLC6A4KMT2A
SCHEMBL13078254 0.69 MAOB (0.44) MAPTKLKB1HTR2ASLC6A4LMNA
SCHEMBL2554863 0.67 MAPT (0.57) MAPTALDH1A1KMT2ALMNAMEN1
SCHEMBL2559484 0.67 MAPT (0.47) SOS1MAPTALDH1A1KMT2ALMNA
SCHEMBL2563053 0.66 MEN1 (0.49) MAPTALDH1A1KMT2ALMNAMEN1
SCHEMBL2561182 0.66 MAPT (0.42) MAPTALDH1A1MAP4K4KMT2ALMNA
SCHEMBL2555365 0.66 MEN1 (0.46) MAPTALDH1A1HTR2ASLC6A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834013-B2 Racemic-(trans)-2-[4-({[3-(phenyloxy)phenyl]methyl}ammonium)phenyl]cyclopropanecarboxylic acid; type II diabetes; G protein-coupled receptor 40 (GPR40) agonists GLAXOSMITHKLINE LLC (US) 2010-11-16 US disclosed
US-20090105257-A1 AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 GLAXOSMITHKLINE LLC 2009-04-23 US disclosed
WO-2005051890-A1 AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 SMITHKLINE BEECHAM CORPORATION (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105257-A1 AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 GPR65, GPR88, GPR84 SOS1 4335/4885MAPT 3025/4885KLKB1 3918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.